Financial Data and Key Metrics Changes - In Q1 2019, total revenues were $9.2 million, down from $25.4 million in the prior-year period, primarily due to lower revenue from collaboration with Sanofi [30] - Net loss for Q1 2019 was $21.8 million or $0.21 per share, compared to a net loss of $41.8 million or $0.40 per share in the same period last year [33] - Cash and short-term investments at the end of Q1 2019 were approximately $133 million, down from $160.1 million as of December 31, 2018 [34] Business Line Data and Key Metrics Changes - US net sales of XERMELO reached $6.7 million in Q1 2019, representing a 24% increase from the same period in 2018 [14] - Research and development expenses decreased to $12 million from $47.7 million in the prior-year period, mainly due to lower external clinical development costs related to sotagliflozin [31] - Selling, general and administrative expenses were $14.1 million in Q1 2019, down from $14.9 million in the same period last year [32] Market Data and Key Metrics Changes - The approval of sotagliflozin in Type I diabetes in Europe marks the second product from the company's labs approved in a major region within 26 months [15] - The first Phase III study results for sotagliflozin in Type II diabetes are expected to be released in the current quarter [16] Company Strategy and Development Direction - The company aims to continue executing its growth strategy focused on the XERMELO business and advancing its pipeline for long-term sustainability [18] - The company is committed to exploring the therapeutic utility of telotristat ethyl in biliary tract cancer and advancing LX9211 for neuropathic pain [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory of XERMELO, expecting 20% or greater growth in US net sales year-over-year [14][36] - The company is well-capitalized to execute its business growth, with a focus on managing resources effectively [17][35] Other Important Information - The company has concluded major Phase III investments in Type I diabetes and is nearing significant milestones for sotagliflozin in Type II diabetes [18] - The anticipated operating expenses for 2019 have been revised to a range of $115 million to $135 million, down from $120 million to $140 million [38] Q&A Session Summary Question: Anticipation of next steps after FDA interactions on Type I diabetes - Management indicated that they still anticipate data release for Type II diabetes this quarter but could not provide a specific timeline for FDA interactions [46][47] Question: Key endpoints for Phase III studies in Type II diabetes - Management highlighted renal impairment studies and a direct comparison with empagliflozin as key areas of focus [50][51] Question: Differentiation of sotagliflozin versus CREDENCE study conclusions - Management noted that A1C reduction will be a key differentiator, alongside renal and hemodynamic effects [59][60] Question: Updates on early-stage pipeline for neuropathic pain - The company is considering diabetic neuropathy as a lead indication for Phase II studies but has not finalized other indications yet [55] Question: Metrics around XERMELO in Q1 2019 - The company reported 104 new patient starts and a 17% growth in TRX for XERMELO in the first quarter [79]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 8800 Technology Forest Place The Woodla ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2018 Earnings Conference Call March 13, 2019 8:00 AM ET Company Participants Kimberly Lee - Head, Investor Relations and Corporate Strategy Lonnel Coats - President, CEO & Director Alexander Santini - EVP & Chief Commercial Officer Pablo Lapuerta - EVP & Chief Medical Officer Jeffrey Wade - EVP, Corporate & Administrative Affairs and CFO Praveen Tyle - EVP, Research & Development Conference Call Participants Liana Moussatos - Wedbush Securities Samantha Semenko ...